clinical trial · NCT05983133
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer·phase1·active not recruiting·n = 68
Colorectal NeoplasmsCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of the Head and NeckPancreatic Ductal AdenocarcinomaPF-08046052
brief summary
This study will test the safety of a drug called PF-08046052/SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. Participants will have cancer that cannot be removed (unresectable) or has spread through the body (metastatic). This study will have three parts. Parts A and B of the study will find out how much PF-08046052/SGN-EGFRd2 should be given to participants. Part C will use the dose found in parts A and B to find out how safe PF-08046052/SGN-EGFRd2 is and if it works to treat solid tumor cancers.
started
Nov 14, 2023
primary completion
Aug 14, 2026
completion
Aug 14, 2026
last updated
Apr 7, 2026
official title
A Phase 1 Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol